CD22/CD19 CAR T and auto-HSCT "sandwich" strategy
SZCART02
Phase 2 other active
Quick answer
CD22/CD19 CAR T and auto-HSCT "sandwich" strategy for B-cell Acute Lymphoblastic Leukemia is a Phase 2 program (other) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- B-cell Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Modality
- other
- Status
- active